DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 74.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 10,562 shares of the biopharmaceutical company’s stock after selling 30,769 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main’s holdings in Regeneron Pharmaceuticals were worth $7,524,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $28,000. Avalon Trust Co purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $36,000. Finally, Private Wealth Management Group LLC raised its stake in Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Robert W. Baird dropped their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a report on Friday, April 25th. Royal Bank of Canada dropped their price target on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating for the company in a research note on Wednesday, April 30th. Citigroup reduced their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $892.60.

Regeneron Pharmaceuticals Trading Down 3.6 %

NASDAQ REGN opened at $527.78 on Friday. The company has a market capitalization of $57.70 billion, a price-to-earnings ratio of 13.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 12 month low of $520.50 and a 12 month high of $1,211.20. The company’s fifty day moving average price is $613.08 and its two-hundred day moving average price is $696.77.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the business posted $9.55 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.67%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.